Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa first-in-human study of DM002 in advanced solid tumors
CTR20263062Phase 2Active
- Sponsor
- Sidao MedTech
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DM002 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), prostate cancer (PCa), endometrial cancer (EC), sponsored by Sidao MedTech. Started Jul 2025; status: active.
02
Drugs
DM002
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)prostate cancer (PCa)endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20263062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263062.